1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Recce Pharmaceuticals Ltd
  6. Summary
    RCE   AU000000RCE5

RECCE PHARMACEUTICALS LTD

(RCE)
Delayed Australian Stock Exchange  -  02:10 2022-06-28 am EDT
0.8500 AUD   +10.39%
06/22Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
AQ
06/21Recce Pharmaceuticals Validates Safety of Anti-Infective Drug in Phase 1 Trial; Shares Rally 15%
MT
06/16RECCE PHARMACEUTICALS : Application for quotation of securities - RCE
PU
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
06/22/2022 06/23/2022 06/24/2022 06/27/2022 06/28/2022 Date
0.84(c) 0.75(c) 0.765(c) 0.77(c) 0.85 Last
1 040 943 378 359 88 581 26 556 295 001 Volume
+27.27% -10.71% +2.00% +0.65% +10.39% Change
More quotes
Estimated financial data (e)
Sales 2020 1,12 M 0,78 M 0,78 M
Net income 2020 -4,32 M -3,00 M -3,00 M
Net cash position 2020 2,60 M 1,81 M 1,81 M
P/E ratio 2020 -19,7x
Yield 2020 -
Sales 2021 1,64 M 1,14 M 1,14 M
Net income 2021 -13,5 M -9,39 M -9,39 M
Net cash position 2021 20,7 M 14,4 M 14,4 M
P/E ratio 2021 -10,7x
Yield 2021 -
Capitalization 137 M 95,0 M 95,0 M
EV / Sales 2020 79,0x
EV / Sales 2021 86,0x
Nbr of Employees -
Free-Float 63,3%
More Financials
Company
Recce Pharmaceuticals Ltd is an Australia-based pharmaceutical company. The Company is engaged in the development and commercialization of a new class of synthetic anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE... 
Sector
Pharmaceuticals
Calendar
09/02Earnings Release
More about the company
All news about RECCE PHARMACEUTICALS LTD
06/22Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clini..
AQ
06/21Recce Pharmaceuticals Validates Safety of Anti-Infective Drug in Phase 1 Trial; Shares ..
MT
06/16RECCE PHARMACEUTICALS : Application for quotation of securities - RCE
PU
05/31RECCE PHARMACEUTICALS : Application for quotation of securities - RCE
PU
05/23Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clini..
AQ
05/20Recce Pharmaceuticals Starts Sixth Cohort Dosing of Antibiotic Drug; Shares Rise 3%
MT
05/19Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I C..
CI
04/13Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High D..
AQ
04/12Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-..
AQ
04/12Recce Pharmaceuticals Doses Human Subjects in RECCE 327 Clinical Trial
MT
04/12RECCE PHARMACEUTICALS : Application for quotation of securities - RCE
PU
04/10Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives
MT
04/10Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong
CI
04/01RECCE PHARMACEUTICALS : Application for quotation of securities - RCE
PU
03/30Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clin..
AQ
More news
News in other languages on RECCE PHARMACEUTICALS LTD
06/21RECCE PHARMACEUTICALS LTD. : Klinische Phase-I-Studie zur Bewertung von RECCE® 327 bei int..
06/21Recce Pharmaceuticals valide l'innocuité d'un médicament anti-infectieux dans un essai ..
05/20RECCE PHARMACEUTICALS LTD. : Recce Pharmaceuticals Ltd.: Klinische Phase-I-Studie zu RECCE..
05/20Recce Pharmaceuticals entame le dosage de la sixième cohorte d'un médicament antibiotiq..
05/19Recce Pharmaceuticals Ltd annonce des données d'innocuité positives pour la cinquième c..
More news
Chart RECCE PHARMACEUTICALS LTD
Duration : Period :
Recce Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECCE PHARMACEUTICALS LTD
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
James Graham Chief Executive Officer, Executive Director & MD
Justin Reynolds Chief Financial Officer
John K. A. Prendergast Non-Executive Chairman
Michele Dilizia Executive Director & Chief Scientific Officer
Thomas Jarrett Operations Manager
Sector and Competitors
1st jan.Capi. (M$)
RECCE PHARMACEUTICALS LTD-25.73%94
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202